How have locoregional, adjuvant, and neoadjuvant therapies for early breast cancer changed? Dr. Mamounas, Medical Director of the Comprehensive Breast Program at Orlando Health UF Health Cancer Center, tells us about therapeutic developments for early breast cancer that were discussed at the 2020 San Antonio Breast Cancer Symposium.

Dr. Ingrid Mayer, the Co-Leader of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center, discusses her topic from the 2020 San Antonio Breast Cancer Symposium.

Returning to speak with us about his recent “View from the Trenches: What Will You Do on Monday Morning?” panel, Dr. William J. Gradishar, Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, explains how physicians can apply key findings from the 2020 San Antonio Breast Cancer Symposium into their practices.

How should we manage breast cancer patients with one to three positive lymph nodes and a low recurrence score? It’s a question we often encounter—and struggle with—in the clinic, but it’s also a question we finally know how to answer thanks to the RxPONDER trial. Here to share the trial’s key findings and what it could mean for pre and postmenopausal women is Dr. Lajos Pusztai, Professor of Medicine and Director of Breast Cancer Translational Research at Yale Cancer Center and Yale School of Medicine.

Although breast cancer mortality rates have declined over the years, many women in racial or ethnic minority groups still have a higher risk of dying. What can we do to fight this disparity? Dr. Mariana Chavez-MacGregor, associate professor at the University of Texas MD Anderson Cancer Center, joins Dr. Charles Turck to investigate treatment differences and discuss how we can eliminate this inequality for patients with early breast cancer.

A critical component in the treatment of patients with non-metastatic early breast cancer is managing the cardiovascular risks associated with its treatment, such as radiation-induced cardiac toxicity. And since this particular threat can put early breast cancer patients at risk of heart failure, Dr. Rachel Jimenez joins Dr. Charles Turck to discuss key prevention strategies.

Patient-reported outcomes, or PROs, are not only an efficient way to measure treatment effects, but they can also help us improve care for patients with early breast cancer. Dr. Charles Turck is joined by Dr. Lola Fayanju to discuss PROs and how they can aid healthcare professionals while treating the early stages of breast cancer.

The 2020 San Antonio Breast Cancer Symposium is set to feature clinical trial updates and advancements in breast cancer care. How will these developments impact the field of breast oncology? Dr. William J. Gradishar, Professor of Medicine at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, shares updates that he's looking forward to at the 2020 SABCS.

Ahead of her workshop at the 2020 San Antonio Breast Cancer Symposium, Dr. Lola Fayanju shares some of the updates in the field of breast cancer that she’s most excited to learn about and how those developments could impact the future of breast cancer care.

The COVID-19 pandemic has led to an influx of hospital admissions, and with limited resources, clinicians are reevaluating the way they manage patients with breast cancer. Here to share how he’s adapted his treatment strategies is Dr. Ben Anderson, Professor of Surgery and Global Health Medicine at the University of Washington.